Herriot Tabuteau

Herriot Tabuteau
Born1968 (age 57–58)
Haiti
Citizenship United States
EducationBachelor of Arts, Wesleyan; Medical Doctor, Yale School of Medicine
OccupationFounder of Axsome Therapeutics
Websitehttps://herriottabuteau.org/about/

Herriot Tabuteau is a Haitian American physician, businessman and entrepreneur. He founded Axsome Therapeutics NasdaqAXSM in 2012.[1][2]

Biography

Dr. Herriot Tabuteau immigrated from Haiti when he was nine years old.[1] Herriot grew up on the Upper East Side of Manhattan[3] He received his medical degree from Yale University School of Medicine and his bachelor's degree in molecular biology and biochemistry from Wesleyan University.[4]

Tabuteau worked in healthcare finance prior to founding Axsome. He was a partner at hedge fund Healthco/S.A.C. Capital.[5]

He took Axsome public in 2015.[6] His 22% stake and options were worth $465 million in 2021 according to Business Insider.[6] As of 2025, he owns 15%.[2][7]

He is listed as the inventor on over 200 patents.[4]

References

  1. ^ a b MFL, Taylor Carmichael, George Budwell, and Patrick (1 April 2022). "3 CEOs to Invest In". The Motley Fool.{{cite web}}: CS1 maint: multiple names: authors list (link)
  2. ^ a b Young, Jabari (2 April 2025). "The World's Black Billionaires 2025". Forbes. Archived from the original on 3 April 2025.
  3. ^ ."About". HerriotTabuteauMD. Archived from the original on 14 April 2025.
  4. ^ a b "Herriot Tabuteau". Forbes. Archived from the original on 6 September 2025. Retrieved 2025-05-26.
  5. ^ "Herriot Tabuteau — Profile". realtimebillionaires.de. Archived from the original on 6 September 2025.
  6. ^ a b Cuccinello, Hayley (29 March 2021). "Meet Dr. Herriot Tabuteau, an elusive doctor whose $2.2 billion pharma company could improve life for millions of people with Alzheimer's". Business Insider. Archived from the original on 30 March 2021.
  7. ^ "The World's Black billionaires in 2025". Daily News on African Billionaires and UHNWIs. 1 April 2025. Archived from the original on 26 July 2025.